Press Releases

 
Press Releases
  Date Title View
Feb 17, 2005
SOUTH SAN FRANCISCO, CA/February 17, 2005 -- Theravance, Inc. (Nasdaq: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to participate in a panel discussion titled "New Antibiotics Against New and Old Threats" at the BIO CEO & Investor Conference to be held Feb. 23-24, 2005 at The Waldorf-Astoria in N...
Feb 16, 2005
Theravance Reports Fourth Quarter And Full Year 2004 Financial ResultsTheravance Reports Fourth Quarter And Full Year 2004 Financial Results Announced Telavancin Phase 2 Study Results Initiated Telavancin Phase 3 Clinical Studies in Hospital Acqui...
Feb 4, 2005
SOUTH SAN FRANCISCO, CA, February 4, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 8, 2005 at 1:15 p.m. ET (10:15 a.m. PT). The conference will b...
Feb 3, 2005
SOUTH SAN FRANCISCO, CA/ February 3, 2005-- Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar will join the Company as Senior Vice President and Chief Financial Officer effective March 7, 2005. Aguiar, previously Vice President of Finance at Gilead Sciences, succeeds Marty Glick, whose move to a newly-created position as Execu...
Jan 31, 2005
SOUTH SAN FRANCISCO, CA/ January 31, 2005-- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended December 31, 2004 after market close on Wednesday, February 16, 2005.An accompanying conference call will be held at 5:00 p.m. Eastern Standard Time. To participate in the live call by t...
Jan 28, 2005
South San Francisco, CA/ January 28, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today it will host an investor presentation luncheon on February 22, 2005 in New York City from noon to 3:00 pm ET to provide a comprehensive review of three of its clinical development programs, including an update of preclinical and clinical study results:...
Jan 26, 2005
South San Francisco, CA/ January 26, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first patient in a Phase 3 clinical study (Assessment of Telavancin for Treatment of MRSA Pneumonia - ATTAIN) of its investigational antibiotic, telavancin, in patients with hospital acquired pneumonia (HAP). ATTAIN is a multination...
Jan 10, 2005
SOUTH SAN FRANCISCO, Calif., January 10, 2005 -- Theravance, Inc. (Nasdaq: THRX) announced today that Rick E Winningham, Theravance's chief executive officer, is scheduled to present at the 23rd Annual JPMorgan Healthcare Conference on Monday, January 10, 2005 at 1:30 p.m. PT (4:30 p.m. ET). The conference will be held from January 10-13 at The Wes...
Jan 7, 2005
SOUTH SAN FRANCISCO, Calif., January 7, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's chief executive officer, is scheduled to present at the 23rd Annual JP Morgan Healthcare Conference on Monday, January 10, 2005 at 1:30 p.m. PT (4:30 p.m. ET). The conference will be held from January 10-13 at ...
Jan 4, 2005
South San Francisco, CA, January 3, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first subjects in a Phase 1 clinical study designed to assess the safety, tolerability and pharmacokinetics of its investigational gastrointestinal (GI) prokinetic, TD-2749. TD-2749 is a selective 5-HT4 agonist discove...
FirstPrevious
...
34
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$13.26 0.16 (1.19%) 11/24/17 12:59 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.